NeuroTherm company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

neurotherm.com

Stage

Acquired | Acquired

Valuation

$0000 

Revenue

$0000 

About NeuroTherm

NeuroTherm is a privately held medical device company that develops, manufactures, and markets solutions for chronic pain. The company is focused on delivering minimally invasive solutions and superior service to its customers in order to realize their shared vision of improving the lives of patients suffering from chronic pain. The company offers proprietary solutions including radiofrequency ablation systems, intradiscal catheters, and a full suite of vertebral augmentation products. The U.S. Patent and Trademark Office has approved over forty NeuroTherm patents including five core radiofrequency technology platform patents, and over twenty additional ancillary patents are currently pending. NeuroTherm's products are available in more than 65 countries with facilities in the metro-Boston area, Amsterdam, Dusseldorf, and London.

NeuroTherm Headquarter Location

600 Research Drive

Wilmington, Massachusetts, 01887,

United States

888-655-3500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

NeuroTherm Patents

NeuroTherm has filed 12 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/30/2013

8/26/2014

Electrotherapy, Neurological disorders, Medical equipment, Neurotechnology, Medical technology

Grant

Application Date

8/30/2013

Grant Date

8/26/2014

Title

Related Topics

Electrotherapy, Neurological disorders, Medical equipment, Neurotechnology, Medical technology

Status

Grant

Latest NeuroTherm News

Continuous But Not Pulsed Radiofrequency Current Generated by NeuroTherm NT500 Impairs Mitochondrial Membrane Potential in Human Monocytic Cells THP-1

Jul 12, 2020

Akira Nishioka,1 Maiko Kimura,1 Eriko Sakamoto,1 Hiroshi Nagasaka,2 Toshiharu Azma1,2 1Department of Anesthesiology & Pain Medicine, Kohondai Hospital, National Center for Global Health and Medicine, Ichikawa, Chiba 272-8516, Japan; 2Department of Anesthesiology, Saitama Medical University Hospital, Iruma, Saitama 350-0495, Japan Correspondence: Toshiharu Azma Department of Anesthesiology & Pain Medicine, Kohondai Hospital, National Center for Global Health and Medicine, Ichikawa, Chiba 272-8516, Japan Email azma@hospk.ncgm.go.jp Background: The application of pulsed radiofrequency (PRF) current to peripheral nerves with conditions related to neuropathic pain is considered to be clinically safe, while it has been reported that the destruction of mitochondria after PRF application was observed by electron microscopy. If it occurs reproducibly, PRF applied to peripheral nerves should provoke neurolysis because the impairment of mitochondria is known as the primary cause of apoptosis. Methods: Human monocytic cells THP-1 loaded with 100 nM tetramethylrhodamine methyl ester (TMRM), a fluorescent dye that proves the mitochondrial membrane potential (MMP), were exposed to the electric field of continuous radiofrequency (CRF) or PRF current. The TMRM-related fluorescence from THP-1 cells was measured by flow cytometry. Results: The exposure of THP-1 cells to a PRF electric field generated by NeuroTherm NT500 for 15 min with maximum power did not decrease MMP in these cells, nor did it cause the induction of apoptosis. By contrast, the application of CRF current at 70 °C for 3 min significantly decreased MMP and induced apoptosis within 10 min after CRF application. Conclusion: We conclude from these findings that PRF application does not provoke mitochondrial injury in various types of mammalian cells because the size and the subcellular structure of the plasma membrane or mitochondria are similar among those. However, the present results cannot address the effect of PRF current on organic structure around the nervous system. Further study is required to solve the question of whether PRF current causes neurolysis or not. Keywords: pulsed radiofrequency current, human monocytic cells, THP-1, mitochondrial membrane potential, apoptosis This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .

  • Where is NeuroTherm's headquarters?

    NeuroTherm's headquarters is located at 600 Research Drive, Wilmington.

  • What is NeuroTherm's latest funding round?

    NeuroTherm's latest funding round is Acquired.

  • Who are the investors of NeuroTherm?

    Investors of NeuroTherm include St. Jude Medical.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.